

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

A dual role for H2A.Z.1 in modulating the dynamics of RNA Polymerase II initiation and elongation

Constantine Mylonas¹, Alexander L. Auld¹, Choongman Lee², Ibrahim I. Cisse², Laurie A. Boyer^{1,3*}

¹Department of Biology, ²Department of Physics, and ³Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139 USA

*Correspondences:
Laurie A. Boyer
lboyer@mit.edu
Tel: +1 617 324-3335

Abstract

RNAPII pausing immediately downstream of the transcription start site (TSS) is a critical rate limiting step at most metazoan genes that allows fine-tuning of gene expression in response to diverse signals¹⁻⁵. During pause-release, RNA Polymerase II (RNAPII) encounters an H2A.Z.1 nucleosome⁶⁻⁸, yet how this variant contributes to transcription is poorly understood. Here, we use high resolution genomic approaches^{2,9} (NET-seq and ChIP-nexus) along with live cell super-resolution microscopy (tcPALM)¹⁰ to investigate the role of H2A.Z.1 on RNAPII dynamics in embryonic stem cells (ESCs). Using a rapid, inducible protein degron system¹¹ combined with transcriptional initiation and elongation inhibitors, our quantitative analysis shows that H2A.Z.1 slows the release of RNAPII, impacting both RNAPII and NELF dynamics at a single molecule level. We also find that H2A.Z.1 loss has a dramatic impact on nascent transcription at stably paused, signal-dependent genes. Furthermore, we demonstrate that H2A.Z.1 inhibits re-assembly and re-initiation of the PIC to reinforce the paused state and acts as a strong additional pause signal at stably paused genes. Together, our study suggests that H2A.Z.1 fine-tunes gene expression by regulating RNAPII kinetics in mammalian cells.

35 **Introduction**

36 Eukaryotic transcription is a highly controlled process facilitated by a compendium of protein
37 complexes that regulate RNA Polymerase II (RNAPII) recruitment as well as transcription
38 initiation, elongation and termination ultimately culminating in genic output³⁻⁵. In metazoans,
39 RNAPII promoter-proximal pausing is now widely recognized as a key rate-limiting step that
40 occurs between +25 to +50 nucleotides downstream of the transcription start site (TSS) and prior
41 to the first nucleosome¹⁻³. Current models suggest that RNAPII pausing provides a critical window
42 of opportunity to fine tune gene expression in response to signaling cues¹². A diverse set of
43 positive and negative factors regulating RNAPII pausing have been extensively studied both *in*
44 *vitro*¹³⁻¹⁵ and *in vivo*^{3,16}, yet how promoter nucleosomes affect pause-release remains poorly
45 understood. At most genes in eukaryotes, the highly conserved histone H2A variant H2A.Z marks
46 nucleosomes that flank the nucleosome depleted region (NDR) around the TSS^{7,17-19}. H2A.Z is
47 essential for early metazoan development^{20,21} and is necessary for proper induction of
48 differentiation programs^{19,22-24}. Conflicting reports suggest both positive and negative functions
49 for H2A.Z in gene regulation. For example, work in *Drosophila* showed that H2A.Z (H2avD) lowers
50 the energy barrier for RNAPII passage⁷, whereas recent biophysical studies using optical
51 tweezers on *in vitro* reconstituted templates demonstrated that mammalian H2A.Z nucleosomes
52 are more stable and pose a greater barrier to RNAPII compared to canonical histone H2A⁶.
53 Notably, disruption of proper H2A.Z incorporation contributes to a growing list of human diseases
54 including cancer^{23,25-27} underscoring the need for dissecting its mechanistic link to transcription in
55 a cellular context.

56

57 **Results**

58 **H2A.Z.1 slows the release of RNAPII towards progressive elongation**

59 In vertebrates, H2A.Z is encoded by two independent genes *H2afz* (H2A.Z.1) and *H2afv* (H2A.Z.2
60 and its smaller spliceoform H2A.Z.2.2) that have distinct expression patterns and developmental
61 roles^{23,24,28}. Because H2A.Z.1 is strongly enriched at most promoters and is required for
62 embryonic development as well as differentiation^{17,19,22,29}, we focused on dissecting how this
63 isoform regulates transcription in mouse embryonic stem cells (ESCs). We generated a
64 homozygous ESC line containing a modified FKBP-V degron tag (dTAG) and 2x-HA epitope at
65 the C-terminus of endogenous H2A.Z.1 (H2A.Z.1^{dTAG}). This system allows for rapid and specific
66 degradation of proteins by addition of the small molecule dTAG-13 (**Fig. 1a and Extended Data**
67 **Fig. 1a,b**)¹¹. Adding dTAG-13 to ESCs led to near complete loss of H2A.Z.1^{dTAG} within 8 hours as

68 shown by immunoblot (**Fig. 1b and Extended Data Fig. 1c**). This system circumvents prior
69 limitations using siRNA knock-down including the extensive time required to assess the
70 consequences of depletion and possible off target effects. CHIP-seq with an anti-HA antibody
71 revealed the highest distribution of H2A.Z.1^{dTAG} over promoters and some distal enhancers,
72 correlating strongly with prior data both at a genome-wide (Spearman R = 0.89) and single gene
73 level (**Extended Data Fig. 1d-f**)¹⁹. Moreover, H2A.Z.1^{dTAG} ESCs were able to form EBs (data not
74 shown) indicating that the dTAG cassette does not interfere with variant incorporation or function.
75 As expected, treating ESCs with dTAG-13 led to rapid and near complete loss of H2A.Z.1 CHIP-
76 seq peaks across the genome within hours (**Fig. 1c and Extended Data Fig.1g**) validating the
77 robustness of our system.

78

79 H2A.Z.1 is enriched at the promoters of most genes including both active (H3K4me3 only) and
80 silent, bivalent (H3K4me3 and H3K27me3) genes in ESCs¹⁷⁻¹⁹. We observed lower H2A.Z.1
81 levels at genes with the highest RNAPII density by CHIP-seq (**Extended Data Fig. 2a**), consistent
82 with more rapid nucleosome turnover during active transcription. To test this idea further, ESCs
83 were treated with the rapid elongation inhibitor DRB (5,6-dichloro-1-beta-D-
84 ribofuranosylbenzimidazole)³⁰, an adenosine analogue that halts mRNA synthesis, followed by
85 RNAPII and H2A.Z.1 CHIP-seq. DRB treatment for 2 hrs led to a decrease in the elongating form
86 of RNAPII S2ph and increase in both RNAPII and H2A.Z.1 density at the promoter-proximal
87 regions of active, but not bivalent genes (**Fig. 1d,e and Extended Data Fig. 2b-f**). Upon DRB
88 wash off, H2A.Z.1 levels decreased at active promoters and RNAPII showed higher levels in gene
89 bodies (**Fig. 1d,e and Extended Data Fig. 2b-d**). These data predict that dTAG-13 treatment will
90 lead to increased transcript levels at genes with the highest H2A.Z.1 enrichment.

91

92 Using RNA-seq, indeed, we found that the vast majority of differentially expressed genes showed
93 increased expression upon rapid H2A.Z.1 loss (**Extended Data Fig. 3a**). We observed a striking
94 inverse correlation between H2A.Z.1 loss at promoters and increased expression of the
95 corresponding gene (Spearman R=-0.63) (**Fig. 1f**). Coupled with our analysis showing an inverse
96 correlation between H2A.Z.1 and RNAPII at promoters, these data suggest that H2A.Z.1
97 regulates RNAPII dynamics. To test this idea, we next performed Native Elongation Transcript
98 Sequencing (NET-seq) to map the strand-specific location of RNAPII at high resolution² in ESCs.
99 Analysis of biological duplicates showed that RNAPII density was highly reproducible (Pearson's
100 R = 0.99 for both control and dTAG data) (**Extended Data Fig. 3b**). Using available START-seq

101 data in ESCs³, we compiled a list of 4,184 uniquely annotated transcription start sites (TSSs)
102 corresponding to non-tandemly oriented protein-coding genes with detectable RNAPII levels
103 (**Extended Data Fig. 3c**). Upon dTAG-13 treatment, RNAPII density significantly decreased at
104 promoters and showed a concomitant increase in the gene body compared to controls (**Fig. 1g**
105 **and Extended Data Fig. 3d**). We then calculated the RNAPII pausing index (PI) which is defined
106 by the density of RNAPII over the promoter proximal region relative to the gene body³¹. A
107 significant decrease ($p = 1.6 \times 10^{-71}$) in the PI was observed upon H2A.Z.1 loss (**Fig. 1h**). ChIP-
108 seq of Spt5, a subunit of the DSIF complex involved in promoter-proximal RNAPII pausing, also
109 showed a global and gene-specific decrease upon dTAG-13 treatment (**Fig. 1i,j**). Together, these
110 data suggest H2A.Z.1 acts as a barrier to transcription by hindering RNAPII pause-release.

111

112 **H2A.Z.1 controls RNAPII and NELF dynamics at single molecule resolution**

113 The above genomic approaches capture a snapshot of RNAPII at either a paused or elongating
114 state, so we next wanted to quantify RNAPII dynamics at single molecule resolution in live cells.
115 We engineered a photoconvertible Dendra2 tag on the largest subunit of endogenous RNAPII
116 (RBP1) in H2A.Z.1^{dTAG} ESCs. ChIP-seq using an anti-Dendra2 antibody confirmed highest
117 RNAPII enrichment at the TSSs of all protein-coding genes, both at a genome-wide and single
118 gene level, strongly correlating with our NET-seq data (Pearson R = 0.75) (**Extended Data Fig.**
119 **4a-c**). Using single molecule super-resolution microscopy (tcPALM)^{10,32} in live
120 H2A.Z.1^{dTAG};RNAPII^{Dendra} ESCs, we found that RNAPII exists both in stable and temporal clusters
121 (~100nm resolution) with an average cluster lifetime of 4.03 ± 0.13 sec (mean \pm SEM of 360
122 clusters) for the latter clusters (**Fig. 2a**). Remarkably, H2A.Z.1 loss increased the average lifetime
123 of temporal RNAPII clusters to 4.47 ± 0.14 sec ($p=0.0066$) (**Fig. 2b**). RNAPII cluster lifetime
124 positively correlates with the rate of RNAPII re-initiation and ultimately mRNA output based on
125 single molecule FISH³²⁻³⁴. In support of this correlation, treatment with the transcription initiation
126 inhibitor triptolide (TRI)³⁵ completely abolished RNAPII cluster dynamics in ESCs, whereas DRB
127 treatment showed a less dramatic effect (**Extended Data Fig. 4d**).

128

129 The significant decrease in the RNAPII pause index and Spt5/DSIF promoter levels upon dTAG-
130 13 treatment as well as single molecule RNAPII cluster dynamics point to a direct role of H2A.Z.1
131 in regulating pause-release. Thus, we next measured the dynamics of other key pausing factors.
132 Negative Elongation Factor (NELF) is a well characterized pausing complex that interacts

133 dynamically with RNAPII upon promoter-release^{4,16,36}. Thus, we analyzed available NELF ChIP-
134 seq data in ESCs³¹ and found a strong overlap with H2A.Z.1 and RNAPII at active gene promoters
135 (**Extended Data Fig. 4e**). To test the prediction that H2A.Z.1 effects NELF dynamics, we
136 engineered a Halo-tag at the C-terminus of endogenous NELF-B, a subunit of the NELF complex,
137 in H2A.Z.1^{dTAG} ESCs (**Extended Data Fig. 4f**). Live cell imaging of NELF-B-Halo showed bright
138 punctate spots in the nucleus as previously described³⁷ (**Fig. 2c**). To next measure NELF cluster
139 dynamics relative to transcription, we treated ESCs for 45 min with either DRB or TRI to inhibit
140 transcription elongation and initiation, respectively. NELF-B-Halo cluster size and intensity were
141 unchanged by blocking initiation (**Fig. 2d**), consistent with the finding that NELF can be recruited
142 to promoter-proximal regions through TFIID interactions³⁸. In contrast, DRB treatment led to a
143 significant decrease in NELF-Halo intensity ($p < 0.007$) and dynamics by blocking elongation and
144 subsequent re-loading or re-initiation of new RNAPII molecules³⁹ (**Fig. 1d,e and Fig. 2d**) Thus,
145 NELF clusters appear to mark regions of active transcriptional elongation in live cells.

146

147 These observations led us to test the dynamic relationship between H2A.Z.1 and NELF within
148 these clusters. We performed fluorescence recovery after photobleaching (FRAP) in
149 H2A.Z.1^{dTAG};NELF-B^{Halo} ESCs. FRAP showed that 81% of NELF was exchanged within ~10
150 seconds in control ESCs similar to the very rapid turnover observed for RNAPII cluster dynamics
151 (**Fig. 2e,f**)¹⁰. Remarkably, NELF clusters displayed a significantly higher recovery (89%; $p = 0.001$)
152 following dTAG-13 treatment suggesting NELF is more rapidly exchanged at active regions upon
153 H2A.Z.1 loss (**Fig. 2f,g**). A similar trend was observed when performing FRAP in the presence of
154 TRI (**Extended Data Fig. 4g,h**), consistent with our imaging data showing that blocking
155 transcription initiation for 45 min does not decrease NELF cluster size due to elongation of
156 engaged RNAPII. Together, measuring RNAPII and NELF dynamics in live cells suggest that
157 H2A.Z.1 impacts both promoter-proximal pause-release and subsequent re-loading of RNAPII.

158

159 **H2A.Z.1 regulates promoter proximal RNAPII half-life**

160 To test this idea that H2A.Z.1 prevents re-initiation presumably due to slowing the release of
161 paused RNAPII at the gene level, we treated H2A.Z.1^{dTAG};RNAPII^{Dendra2} ESCs with TRI at different
162 timepoints (10, 20, and 40 min) and performed ChIP-nexus⁹, a protocol that captures both
163 initiating and stalled RNAPII at nucleotide resolution (**Fig. 3a**). As TRI treatment blocks new
164 initiation³⁵, paused RNAPII is eventually lost either by release of the elongation complex into the

165 gene body or by premature termination of nascent transcripts⁴⁰. As expected, TRI treatment
166 caused a dramatic decrease of promoter-proximal RNAPII at active genes in both control and
167 dTAG-13 treated ESCs (**Extended Data Fig. 5a,b**). CHIP-nexus also revealed a lower RNAPII
168 pausing index upon H2A.Z.1 depletion compared to controls consistent with our NET-seq data
169 (**Fig. 1h**) and with a more rapid RNAPII release into gene bodies (**Extended Data Fig. 5c**).

170 RNAPII half-life can be used as a measure of its turnover at gene promoters. Thus, we next fitted
171 an exponential decay model using the time points of TRI treatment considering only those genes
172 that maintain measurable RNAPII levels throughout the time course (see Methods). We calculated
173 a median RNAPII half-life of 8.97 min in control ESCs (n = 2,971 genes), in good agreement with
174 data in both *Drosophila*^{39,41} and mammalian cell lines⁴⁰. In contrast, RNAPII half-life decreased to
175 7.70 min (p = 1x10⁻¹²²) upon dTAG-13 treatment (**Fig. 3b,c**). We then performed k-means
176 clustering and divided genes into three categories based on RNAPII half-life/turnover in control
177 ESCs: Short; 1.5-7.9 min (n = 1,449), Medium; 8-13.5 min (n = 730), and Long; 13.6 – 23.5 min
178 (n = 728) (**Fig. 3d**). Following dTAG-13 treatment, RNAPII half-life was most dramatically reduced
179 at genes displaying shorter half-lives (Short p = 1x10⁻⁶⁹, Medium p = 2.1x10⁻³¹) (**Fig. 3d**).
180 Surprisingly, although RNAPII half-life of more stably paused genes did not change appreciably
181 upon H2A.Z.1 loss (Long p = 0.4), these genes exhibited a dramatic decrease of promoter-
182 proximal RNAPII followed by a concomitant increase in nascent transcripts (**Fig. 3e-g**). Upon DRB
183 treatment, we observed that genes with a longer RNAPII half-life also displayed a dramatic shift
184 of RNAPII into the gene body upon release from the elongation block (**Extended Data Fig. 5d**).
185 Moreover, H2A.Z.1 slows pause-release and nascent transcription at stably paused genes, a
186 class of genes that appear most sensitive to signalling cues^{3,39}. Notably, these stably paused
187 genes show lower expression in ESCs and have higher promoter GC content (**Extended Data**
188 **Fig. 5d-g**), a sequence feature associated with stable RNAPII pausing in metazoans^{42,43}. Thus,
189 limiting pause release and subsequent RNAPII loading may safeguard proper activation of
190 H2A.Z.1 genes.

191

192 **H2A.Z.1 controls Pre-initiation complex (PIC) recruitment at promoters**

193 Our observations suggest that stably paused genes experience more rapid reloading of RNAPII
194 upon H2A.Z.1 depletion. Although our tcPALM data are consistent with an overall increase in
195 initiating RNAPII upon dTAG-13 treatment (**Fig. 2b**), we wanted to measure RNAPII PIC
196 recruitment and initiation at individual promoters. RNAPII CHIP-nexus in combination with TRI

197 treatment showed a dramatic increase in initiating Serine 5 phosphorylated CTD levels (RNAPII
198 S5ph) (**Extended Data Fig. 6a**) and shift of RNAPII occupancy upstream of the TSS (**Fig. 4a**)
199 consistent with the position of the PIC^{39,44}. Notably, after 40 min of TRI treatment, we observed
200 similarly higher initiating RNAPII levels in dTAG-13 treated compared to control ESCs (**Fig. 4b**
201 **and Extended Data Fig. 6b,c**).

202

203 To validate that the increase in initiating RNAPII upon H2A.Z.1 loss is due to new PIC recruitment,
204 we next performed ChIP-nexus for the PIC subunits TFIIB and TBP to map their location at base
205 pair resolution. Both TFIIB and TBP displayed a strong enrichment ~20-30bp upstream of the
206 TSS with high reproducibility between biological replicates (**Fig. 4c and Extended Data Fig.**
207 **7a,b**). *In vitro*, PIC dynamics is on the order of seconds^{14,45-47} and promoter proximal paused
208 RNAPII is refractory to new transcription initiation³⁹. To first measure new TFIIB and TBP
209 enrichment, we treated cells with TRI for 40 min to enable complete release of paused RNAPII.
210 ChIP-nexus revealed an increase of new PIC recruitment at RNAPII-dependent promoters either
211 upon TRI and/or dTAG-13 treatment (**Fig. 4d-f and Extended Data Fig. 7c-e**) with the most
212 dramatic increase observed at stably paused (Long) promoters (**Extended Data Fig. 7f**).
213 Collectively, our data support a model whereby H2A.Z.1 enables multistep control of transcription
214 by slowing RNAPII pause-release which subsequently inhibits PIC assembly and re-initiation.

215

216 RNAPII pausing is critical to allow genes to appropriately respond to developmental and
217 environmental signals by controlling the timing, rate, and magnitude of the transcriptional
218 response^{3,44,48}. In addition to known pausing factors, our quantitative molecular analysis provides
219 strong evidence that H2A.Z.1 acts as a barrier to transcription, affecting both RNAPII pause-
220 release and re-engagement of new RNAPII at promoters in mammalian cells (**Fig. 4g**). Thus,
221 H2A.Z.1 likely coordinates synchronous gene expression in response to signaling cues.
222 Consistent with this idea, stably paused genes show more synchronous expression, lower cell to
223 cell variability, and are typically signal-responsive genes⁴⁹. Thus, H2A.Z.1 may serve as a GO or
224 NO-GO decision point whereby RNAPII can either undergo early transcript termination or
225 progressive elongation depending on cellular signals. Notably, in the absence of NELF, RNAPII
226 experiences a second pause around the +1 nucleosome dyad¹⁶. Our data argue that site-specific
227 H2A.Z incorporation surrounding the NDR is critical for this additional pause. Thus, our data also
228 predict that H2A.Z.1 nucleosomes upstream of the TSS play a role in regulating PIC assembly

229 and re-initiation. Together, our work uncovers a mechanistic link between H2A.Z.1 and
230 transcription dynamics and provides an explanation for its promoter enrichment at RNAPII-
231 regulated genes and requirement in metazoan development.

232

233 **Acknowledgements**

234 We thank the Boyer lab, Seychelle Vos, Eliezer Calo and Craig Peterson for helpful discussions
235 and insightful comments on the manuscript. This work was supported by NIGMS R01-GM134734
236 to I.C., NHLBI R01-HL140471 to L.A.B. and the Koch Institute Core Grant P30-CA14051 from the
237 National Cancer Institute.

238

239 **Accession Numbers**

240 Raw and normalized sequencing data has been deposited under GEO accession number
241 GSEXXXXXXX.

242

243 **Author Contributions**

244 CM and LAB designed the study. CM performed experiments and analyzed data. AA assisted
245 with FRAP image acquisition and analysis. CL and IC assisted with tcPALM. CM and LAB wrote
246 the manuscript with input from all authors.

247

248

249

250

251

252

253

254

255

256

257 **Materials and Methods**

258 **ESC culture**

259 V6.5 murine embryonic stem cells (mESC) were cultured in 2i + LIF conditions⁵⁰ for all
260 assays. Genome editing was performed in serum + LIF conditions. Cells were cultured at 37°C,
261 5% CO₂, on 0.1% gelatin coated tissue culture plates. The media used for general culturing in
262 serum + LIF conditions is as follows: DMEM-KO (Invitrogen 10829-018) supplemented with
263 15% fetal bovine serum (Hyclone characterized SH3007103), 1,000 U/ml LIF,
264 100 mM nonessential amino acids (Invitrogen 11140-050), 2 mM L-glutamine (Invitrogen 25030-
265 081), 100 U/mL penicillin, 100 mg/mL streptomycin (Invitrogen 15140-122), and 8 ul/mL of 2-
266 mercaptoethanol (Sigma M7522). The media used for 2i + LIF media conditions is as follows:
267 484 mL DMEM/F12 (GIBCO 11320), 2.5 mL N2 supplement (GIBCO 17502048), 5 mL B27
268 supplement (GIBCO 17504044), 0.5 mM L-glutamine (GIBCO 25030), 1X non-essential amino
269 acids (GIBCO 11140), 100 U/mL Penicillin-Streptomycin (GIBCO 15140), 0.1 mM β-
270 mercaptoethanol (Sigma M6250), 1 uM PD0325901 (Stemgent 04-0006), 3
271 uM CHIR99021 (Stemgent 04-0004), and 1000 U/mL recombinant LIF.

272

273 **Immunoblots**

274 To assay immunoprecipitation results by western blot, 500ng of each sample was run on a 4%–
275 20% Bis-Tris gel (Bio-rad 3450124) using SDS running buffer (Bio-rad 1610788) at 120V for 10
276 minutes, followed by 180V until dye front reached the end of the gel. Protein was then wet
277 transferred to a nitrocellulose membrane using the Trans-blot turbo transfer system (Bio-rad).
278 After transfer, the membrane was blocked with 5% BSA for 1h on a rotor.

279 Membrane was then incubated with 1:5000 Anti-HA (Cell Signaling 3724), 1:1000 Anti-Nelf-B
280 (Cell Signaling 14894), 1:1000 Anti-RNAPII S5ph (Active Motif 39750), 1:1000 Anti-RNAPII S2ph
281 (Active Motif 39564), 1:1000 Anti-GAPDH (Cell Signaling 8884) diluted in 5% BSA in TBST and
282 incubated for 2h at room temperature. Following several washes with TBST, membranes were
283 incubated either with 1:10,000 Anti-mouse HRP (Cell Signaling 7076) or with 1:10,000 Anti-rabbit
284 HRP (R&D Systems FIN1818061) for 1h at room temperature with rotation. After extensive wash
285 with TBST, membranes were developed with ECL substrate (Bio-rad 1705060) and imaged using
286 Azure 600 or exposed using film.

287 **Chromatin Immunoprecipitation (ChIP)**

288 ChIP was performed using ~10 million ESCs per assay as previously described⁵¹. Briefly, cells
289 were cross-linked with 1% formaldehyde for 10 min followed by 5 min quenching with
290 125 mM glycine. After washing with PBS buffer, the cells were collected and lysed in cell lysis
291 buffer (5 mM Tris, pH 8.0, 85 mM KCl, and 0.5% NP-40) with x1 Halt Protease Inhibitor cocktail
292 (ThermoFisher 87786) and 1mM PMSF (Sigma 10837091001). Pellets were spun for 5 min at
293 6000 rpm at 4°C. Nuclei were lysed in nuclei lysis buffer (1% SDS, 10 mM EDTA, and 50 mM
294 Tris–HCl) and samples were sonicated for 12 min on a Covaris Sonicator. The samples were
295 centrifuged for 20 min at 13,000 rpm at 4°C and the supernatant was diluted in IP buffer (0.01%
296 SDS, 1.1% Triton-X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl, and 167 mM NaCl), and the
297 appropriate antibody (10 µg) was added and incubated overnight at 4°C with rotation. Antibodies

298 used in this study; Anti-HA (Cell Signaling 3724), Anti-Spt5 (Santa Cruz sc-133217), Anti-Dendra2
299 (OriGene TA180094), Anti-TFIIB (Cell Signaling 4169), Anti-TBP (Abcam, ab28175). Two
300 biological replicates were prepared for each condition using independent cell cultures and
301 chromatin precipitations. Following overnight incubation, 50 μ l Protein G Dynabeads (Life
302 Technologies 10009D) were added for 1 h at room temperature with rotation. Beads were washed
303 once for 1 min with rotation with each of the following buffers: Low salt buffer (0.1% SDS, 1%
304 Triton-X-100, 2mM EDTA, 20mM Tris pH 8.0, 150mM NaCl), High salt buffer (0.1% SDS, 1%
305 Triton-X-100, 2mM EDTA, 20mM Tris pH 8.0, 500mM NaCl), LiCl buffer (0.25M LiCl, 1% NP-40,
306 1% dioxycholate, 10mM Tris pH 8.0, 1mM EDTA), and TE buffer (50mM Tris pH 8.0 , 10mM
307 EDTA). DNA was eluted off the beads by rotation at room temperature for 30 min in 200 μ L elution
308 buffer (1% SDS, 0.1M NaHCO₃). Cross-links were reversed at 65°C for 4h. RNA was degraded
309 by the addition of 3 μ L of 33 mg/mL RNase A (Sigma R4642) and incubation at 37°C for 2 hours.
310 Protein was degraded by the addition of 5 μ L of 20 mg/mL proteinase K (Invitrogen 25530049)
311 and incubation at 50°C for 1 hour. Phenol:chloroform:isoamyl alcohol extraction was performed
312 followed by ethanol precipitation, the resulting DNA was resuspended in 20 μ L H₂O, and used for
313 either qPCR or sequencing.

314 For ChIP-seq experiments, purified 10-20 ng of ChIP DNA was used to prepare Illumina
315 multiplexed sequencing libraries. Libraries for Illumina sequencing were prepared following the
316 NEBNext DNA Library Prep Master Mix kit (NEB E6040). Amplified libraries were size selected
317 using a 2% agarose gel to extract fragments between 200 and 600 bp.

318

319 **ChIP-nexus**

320 For each ChIP we used ~20 million crosslinked mouse ESCs spiked-in with 5% human U2OS
321 cells expressing Dendra2-RNAPII to account for loss of RNAPII during triptolide treatment. For
322 TBP and TFIIB ChIPs, mouse ESCs were spiked-in with 5% human iPSCs cells. ChIP was
323 performed as described above. The ChIP-nexus libraries were constructed as previously
324 described with minor modifications⁹. IPed-bead bound material was End-repaired, followed by
325 dA-tailing and adaptor ligation. The ChIP-nexus adaptor mix contained four fixed barcodes
326 (ACTG, CTGA, GACT, TGAC). Barcode was extended with Phi29 polymerase, followed by λ
327 exonuclease digestion, ethanol precipitation and ssDNA circularization. A detailed ChIP-nexus
328 protocol can be found online ([ChIP-nexus protocol v.2019](#)). At least two biological replicates were
329 performed for each factor to obtain coverage of at least 80 million reads per condition. Single-end
330 sequencing of 75 bp was performed on an Illumina NextSeq 500 instrument.

331

332 **ChIP-seq/nexus analysis**

333 For ChIP-seq, the samples were single-end deep-sequenced and reads were aligned to the
334 mm10 genome using Bowtie2 (v 2.3.5)⁵². Peak calling was performed using PePr (v 1.1)⁵³ with
335 peaks displaying an FDR < 10⁻⁵ considered statistically significant. All aligned ChIP-seq BAM files
336 were converted to bigwig (10 bp bin) and normalized to 1x sequencing depth using deepTools (v

337 3.0)⁵⁴. Blacklisted mm10 coordinates were further removed from the analysis. Average binding
338 profiles were visualized using R (v 3.6.1). Heatmaps were generated with deepTools.

339 For ChIP-nexus, fastq files were filtered for the presence of the four mixed barcodes and were
340 deduplicated using Q-Nexus⁵⁵. Bowtie2 (v 2.3.5) was used for alignment to either the mm10 or
341 hg19 genome. Normalization factors were computed for reads mapping uniquely to the human
342 genome using Deseq2⁵⁶. All aligned mouse ChIP-nexus BAM files were converted to bigwig (1
343 bp bin), separated by strand, and normalized to human spike-in controls using deepTools (v 3.0)
344 with an “-offset 1” to record the position of the 5’ end of the sequencing read which corresponds
345 to TF footprint.

346 To calculate the half-life of paused RNAPII for each gene, RNAPII density was calculated in a
347 250-bp window around the TSS. RNAPII time-course measurements were fitted into an
348 exponential decay model using the “RNAdecay”⁵⁷ R package. We selected genes fulfilling the
349 current criteria; 1) detectable RNAPII levels (RPM > 0.1), 2) highest RNAPII density at “No TRI”
350 condition, and 3) low variance between replicates (sigma < 0.05). Genes fitting the above criteria
351 (n = 2,971) were used to calculate RNAPII half-life. The full list of genes is displayed in **Extended**
352 **Data Table 1**.

353 **Genome Editing using CRISPR/Cas9**

354 The CRISPR/Cas9 system was used to genetically engineer ESC lines. Target-specific
355 oligonucleotides were cloned into the pSpCas9-GFP plasmid (Addgene PX458) using BbsI
356 restriction digestion. The oligo sequences used for cloning are;

H2A _{fz} _sgRNA	(forward) CACCGAAGACTGTTTAAGGATGCC
	(reverse) AAACGGCATCCTTAAACAGTCTTC
RBP1_sgRNA	(forward) CACCGAGTCCTGAGTCCGGATGAAT
	(reverse) AAACATTCATCCGGACTCAGGACTC
Nelfb_sgRNA	(forward) CACCGCCAGCCACACTGTGAGGCTG
	(reverse) AAACCAGCCTCACAGTGTGGCTGGC

357
358 Plasmids containing H2afz- FKBP.knock-in.BFP and Nelfb-Halo DNA repair templates were
359 synthesized with long homology arms (~800 bp) by Genewiz FragmentGene and assembled
360 using the NEBuilder HiFi DNA Assembly Cloning kit (NEB E5520S). The Dendra2-RBP1 plasmid
361 and guide were used as previously described¹⁰.

362 For the generation of the endogenously tagged lines, 1 million mES cells were transfected with
363 1.25 µg Cas9 plasmid and 1.25 µg non-linearized repair template plasmid. Cells were sorted after
364 30 hours for the presence of Cas9-GFP. Cells were expanded for five days and then sorted again
365 either for BFP (H2afz-FKBP) or GFP (RBP1-Dendra2). Cells that were transfected with the Nelfb-
366 Halo repair template were incubated for 15 min with 500nM Halo TMR ligand (Promega G8251),
367 washed 3 times with 2i media and further incubated for another 30 min before sorting for Texas
368 Red. Sorted cells were plated at a low density (~400 cells) on 10cm plates with irradiated MEFs
369 and grown for approximately one week. Individual colonies were picked using a stereoscope into

370 a 96-well plate. Cells were expanded and genotyped by PCR. Clones with a homozygous knock-
371 in tag were further expanded and used for experiments.

372

373 **Super-resolution imaging**

374 Live cell PALM imaging was carried out as described before¹⁰. Briefly, cells were incubated in L-
375 15 medium and were simultaneously illuminated with 1.3 W/cm² near UV light (405nm) for
376 photoconversion of Dendra2 and 3.2 kW/cm² (561nm) for fluorescence detection with an
377 exposure time of 50ms. We acquired images of Dendra2-RNAPII for 50s (1000 frames) for
378 quantification of transient clusters. Super-resolution images were reconstructed using MTT⁵⁸ and
379 qSR⁵⁹. For imaging NELFb-Halo clusters, cells were incubated for 15 min with 500nM Halo TMR
380 ligand (Promega G8251), washed with 2i media three times followed by 30 min incubation in 2i
381 media without the ligand to remove unbound HaloTaq ligands before fluorescence imaging in L-
382 15 medium. We acquired 100 frames (5s) with 561nm excitation.

383

384 **Density based spatial clustering of applications with noise (DBSCAN) analysis**

385 We used a clustering algorithm, density based spatial clustering of applications with noise
386 (DBSCAN), to define the area of clustered regions in super-resolution data, as previously
387 described¹⁰. Based on the single molecule localization in a super-resolution image, DBSCAN tests
388 if a localization can be grouped with nearby localizations. Once a localization has a minimum
389 number of nearby localizations (N) within a specific distance (R), it is grouped with other
390 localizations also satisfying N and R criteria in their local neighbourhood. We defined the
391 parameters N = 25-30 (points) and R = 90-95 (nm) for Dendra2-RNAPIII clustering. Varying the
392 parameters for an image, we chose a set of parameters (N, R) for which the DBSCAN clustering
393 result agrees with intensified regions in the super-resolution image generated using the qSR
394 software module. For DBSCAN analysis, we used the 'DBSCAN' module embedded in the qSR
395 software.

396

397 **Fluorescence Recovery After Photobleaching (FRAP)**

398 FRAP experiments were carried out as previously described¹⁰. Images were taken at a single
399 confocal plane with an exposure time of 200ms. The bleach spot was taken at the center of each
400 cluster and images were acquired at 1s intervals for 1min. Imaging was done on an Andor
401 Revolution Spinning Disk Confocal microscope was used with the FRAPPA module. To quantify
402 FRAP recovery, photobleaching was corrected by normalizing to non-bleached areas using the
403 FIJI plugin FRAP profiler (<http://worms.zoology.wisc.edu/research/4d/4d>).

404 **RNA-isolation and sequencing**

405 RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN 74136) according to manufacturer's
406 instructions. ERCC spike-in controls were added to the RNA samples prior to library
407 preparation. Stranded Ribo-depleted selected libraries were prepared using the TruSeq
408 Stranded mRNA Library Prep Kit (Illumina RS-122-2101) according to manufacturer's standard

409 protocol. Libraries were subject to 75 bp paired-end end sequencing on an Illumina NextSeq
410 instrument.

411

412 **RNA-seq analysis**

413 Sequenced reads were aligned to the mm10 genome via STAR (v 2.7.2b)⁶⁰. Gene counts were
414 obtained from featureCounts of the Rsubread package (R/Bioconductor). Only genes with CPM
415 > 2 were included in subsequent analysis. Normalization factors from ERCC spike-in controls
416 were calculated using edgeR⁶¹ and applied to the counts mapping to the mm10 genome.
417 Differential expression was performed using the limma⁶² package. Significant genes with an
418 absolute Fold change > 1.5 and adjusted *P*-value < 0.05 were considered as differentially
419 expressed (**Extended Data Table 2**).

420

421 **Cell fractionation, RNA preparation and sequencing library construction for NET-seq**

422 The cell fractionation was performed as described previously⁶³. 10 million ES cells are washed
423 with 500 ml of pre-cooled 1x PBS, resuspended in 150 ml Cytoplasmic lysis buffer (0.15% (v/v)
424 NP-40, 10 mM Tris-HCl (pH 7.0), 150 mM NaCl, 25 mM a-amanitin (MCE HY-19610), 50 U
425 SUPERase.In (Life Technologies AM2694), x1 Halt Protease Inhibitor cocktail mix (ThermoFisher
426 87786) and incubated on ice for 5 min. The cell lysate is layered over 400 ml of Sucrose buffer
427 (10 mM Tris-HCl (pH 7.0), 150 mM NaCl, 25% (w/v) sucrose, 25 mM a-amanitin, 50 U
428 SUPERase.In, x1 Halt Protease Inhibitor cocktail mix) and centrifuged at 16,000 g for 10 min at
429 4C. The nuclei pellet is resuspended in 500 ml Nuclei wash buffer (0.1% (v/v) Triton X-100, 1 mM
430 EDTA, in 1x PBS, 25 mM a-amanitin, 50 U SUPERase.In, 1x Protease inhibitor mix) and
431 centrifuged at 1,150 g for 1 min at 4C. Washed nuclei are resuspended in 200 ml Glycerol buffer
432 (20 mM Tris-HCl (pH 8.0), 75 mM NaCl, 0.5 mM EDTA, 50% (v/v) glycerol, 0.85 mM DTT, 25 mM
433 a-amanitin, 50 U SUPERase.In, 1x Protease inhibitor mix). Next, 200 ml of Nuclei lysis buffer (1%
434 (v/v) NP-40, 20 mM HEPES pH 7.5, 300 mM NaCl, 1M Urea, 0.2 mM EDTA, 1 mM DTT, 25 mM
435 a-amanitin, 50 U SUPERase.In, 1x Protease inhibitor mix) are added, mixed by pulsed vortexing
436 and incubated on ice for 2 min. The lysate is centrifuged at 18,500 g for 2 min at 4C. The chromatin
437 pellet is resuspended in 50 ml Chromatin resuspension solution (25 mM a-amanitin, 50 Units
438 SUPERase.In, 1x Protease inhibitor mix in 1x PBS) before RNA preparation. Biological replicates
439 were obtained from two independent Control and dTAG-13 treated cells. Prior to library
440 preparation, SIRV spike-in controls (1:10,000 dilution) were added to the extracted RNA to
441 account for loss of RNA during library preparation. NET-seq library construction was conducted
442 as originally described⁵⁰.

443 More than 90% recovery of ligated RNA and cDNA was achieved from 15% TBE-Urea (Invitrogen
444 EC6885BOX) and 10% TBE-Urea (Invitrogen EC6875BOX), respectively, by adding RNA
445 recovery buffer (R1070-1-10; Zymo Research) to the excised gel slices and further incubating at
446 70°C (1,500 rpm) for 15 min. Gel slurry was added to a ZymoSpin IV Column (Zymo Research
447 C1007-50) and cDNA was precipitated for subsequent library preparation steps. cDNA containing
448 the 3' end sequences of a subset of mature and heavily sequenced snRNAs, snoRNAs, and

449 rRNAs were specifically depleted using biotinylated DNA oligos⁵⁰. Oligo-depleted circularized
450 cDNA was amplified by PCR and double-stranded DNA was run on a 3% low melt agarose gel.
451 The final NET-seq library running at ~150 bp was extracted and further purified using the
452 ZymoClean Gel DNA recovery kit (Zymo Research D4007). Sample purity and concentration was
453 assessed in a 2200 TapeStation and further deep sequenced in a HiSeq 2500 Illumina Platform.

454

455

456 **Processing and alignment of NET-seq reads**

457 All the NET-seq FASTQ files were processed using custom Python scripts
458 (<https://github.com/BradnerLab/netseq>). The sequencing reads are aligned to the mouse
459 reference genome (mm10) using the STAR (v 2.7.2b) aligner⁶⁰. PCR duplicates and reads arising
460 from RT bias were also removed. Reads mapping exactly to the last nucleotide of each intron and
461 exon (splicing intermediates) were further removed from the analysis. The final NET-seq BAM
462 files were converted to bigwig, separated by strand, and normalized to SIRV spike-in controls
463 using deepTools (v 3.0) with an “-offset 1” to record the position of the 5’ end of the sequencing
464 read which corresponds to the 3’ end of the nascent RNA. NET-seq tags sharing the same or
465 opposite orientation with the TSS were assigned as “sense” and “antisense” tags, respectively.
466 Promoter-proximal regions were carefully selected for analysis to ensure that there is minimal
467 contamination from transcription arising from other transcription units. Genes overlapping within
468 a region of 2 kb upstream of the TSS were removed from the analysis.

469

470 **RNAPII pausing index calculation**

471 The RNAP II pausing index is determined by dividing the coverage in the region -30 to +250 bp
472 around transcription start sites by the coverage in the region +300 bp downstream of the TSS to
473 the transcription end site. The analysis was performed for non-overlapping protein-coding genes
474 displaying a detectable signal of RNAPII (RPM > 0.1) at the promoter proximal region.

475

476 **Publicly available ChIP-seq data**

477 H3K4me3;H3K27Ac;H3K27me3 (GSE47950)⁶⁴, H2A.Z.1-GFP (GSE40063)¹⁹, RING1B
478 (GSE69955)⁶⁵. *Bona fide* active (H3K4me3 only) and bivalent (H3K4me3 & H3K27me3) gene co-
479 ordinates were downloaded from Mas *et al* 2018⁶⁶.

480

481

482

483

484 **References**

- 485 1. Kwak, H., Fuda, N. J., Core, L. J. & Lis, J. T. Precise Maps of RNA Polymerase Reveal
486 How Promoters Direct Initiation and Pausing. *Science* **339**, 950-953 (2013).
- 487 2. Mayer, A. *et al.* Native elongating transcript sequencing reveals human transcriptional
488 activity at nucleotide resolution. *Cell* **161**, 541–544 (2015).
- 489 3. Williams, L. H. *et al.* Pausing of RNA Polymerase II Regulates Mammalian
490 Developmental Potential through Control of Signaling Networks. *Mol. Cell* **58**, 311–322
491 (2015).
- 492 4. Lee, C. *et al.* NELF and GAGA Factor Are Linked to Promoter-Proximal Pausing at Many
493 Genes in Drosophila. *Mol. Cell Biol.* **28**, 3290–3300 (2008).
- 494 5. Jonkers, I. & Lis, J. T. Getting up to speed with transcription elongation by RNA
495 polymerase II. *Nat Rev Mol Cell Biol* **16**, 167–177 (2015).
- 496 6. Chen, Z. *et al.* High-resolution and high-accuracy topographic and transcriptional maps of
497 the nucleosome barrier. *Elife* **8**:e48281 (2019).
- 498 7. Weber, C. M., Ramachandran, S. & Henikoff, S. Nucleosomes are context-specific,
499 H2A.Z-Modulated barriers to RNA polymerase. *Mol. Cell* **53**, 819–830 (2014).
- 500 8. Jang, C. W., Shibata, Y., Starmer, J., Yee, D. & Magnuson, T. Histone H3.3 maintains
501 genome integrity during mammalian development. *Genes Dev.* **29**, 1377–1393 (2015).
- 502 9. He, Q., Johnston, J. & Zeitlinger, J. ChIP-nexus enables improved detection of in vivo
503 transcription factor binding footprints. *Nat. Biotechnol.* **33**, 395–401 (2015).
- 504 10. Cho, W.-K. *et al.* Mediator and RNA polymerase II clusters associate in transcription-
505 dependent condensates. *Science* **6400**, 412-415 (2018).
- 506 11. Nabet, B. *et al.* The dTAG system for immediate and target-specific protein degradation.
507 *Nat. Chem. Biol.* **14**, 431–441 (2018).
- 508 12. Core, L. & Adelman, K. Promoter-proximal pausing of RNA polymerase II: a nexus of
509 gene regulation. *Genes Dev.* **33**, 960–982 (2019).
- 510 13. Vos, S. M., Farnung, L., Urlaub, H. & Cramer, P. Structure of paused transcription
511 complex Pol II–DSIF–NELF. *Nature* **560**, 601–606 (2018).

- 512 14. Sainsbury, S., Bernecky, C. & Cramer, P. Structural basis of transcription initiation by
513 RNA polymerase II. *Nat Rev Mol Cell Biol* **16**, 129–143 (2015).
- 514 15. Yamaguchi, Y. *et al.* NELF, a Multisubunit Complex Containing RD, Cooperates with
515 DSIF to Repress RNA Polymerase II Elongation. *Cell* **97**, 41–51 (1999).
- 516 16. Aoi Y, Smith ER, Shah AP, *et al.* NELF Regulates a Promoter-Proximal Step Distinct from
517 RNA Pol II Pause-Release. *Mol Cell* **78**(2), 261-274 (2020).
- 518 17. Hu, G. *et al.* H2A.Z facilitates access of active and repressive complexes to chromatin in
519 embryonic stem cell self-renewal and differentiation. *Cell Stem Cell* **12**, 180–192 (2013).
- 520 18. Ku, M. *et al.* H2A.Z landscapes and dual modifications in pluripotent and multipotent stem
521 cells underlie complex genome regulatory functions. *Genome Biol.* **13**(10) R85 (2012).
- 522 19. Subramanian, V. *et al.* H2A.Z Acidic Patch Couples Chromatin Dynamics to Regulation of
523 Gene Expression Programs during ESC Differentiation. *PLoS Genet.* **9** (8) (2013).
- 524 20. Maze, I., Noh, K.-M., Soshnev, A. A. & Allis, C. D. Every amino acid matters: essential
525 contributions of histone variants to mammalian development and disease. *Nat. Rev.*
526 *Genet.* **15**, 259–271 (2014).
- 527 21. Subramanian, V., Fields, P. A. & Boyer, L. A. H2A.Z: a molecular rheostat for
528 transcriptional control. *F1000Prime Rep.* **7** (01), (2015).
- 529 22. Faast, R. *et al.* Histone variant H2A.Z is required for early mammalian development. *Curr.*
530 *Biol.* **11**, 1183–1187 (2001).
- 531 23. Greenberg, R. S., Long, H. K., Swigut, T. & Wysocka, J. Single Amino Acid Change
532 Underlies Distinct Roles of H2A.Z Subtypes in Human Syndrome. *Cell* **178**, 1421-1436
533 (2019).
- 534 24. Lamaa, A. *et al.* Integrated analysis of H2A.Z isoforms function reveals a complex
535 interplay in gene regulation. *Elife* **9**, e53375 (2020).
- 536 25. Reschen, M. *et al.* Floating–Harbor syndrome and polycystic kidneys associated with
537 SRCAP mutation. *Am. J. Med. Genet. Part A* **158A**, 3196–3200 (2012).
- 538 26. Chen, I. Y. *et al.* Histone H2A.z is essential for cardiac myocyte hypertrophy but opposed
539 by silent information regulator 2a. *J. Biol. Chem.* **281**, 19369–19377 (2006).
- 540 27. Svoltelis, A., Gevry, N., Grondin, G. & Gaudreau, L. H2A.Z overexpression promotes

- 541 cellular proliferation of breast cancer cells. *Cell Cycle* **9**, 364–370 (2010).
- 542 28. Dryhurst, D. *et al.* Characterization of the histone H2A.Z-1 and H2A.Z-2 isoforms in
543 vertebrates. *BMC Biol.* **7**, 1–16 (2009).
- 544 29. Schones, D. E. *et al.* Dynamic regulation of nucleosome positioning in the human
545 genome. *Cell* **132**, 887–898 (2008).
- 546 30. Chen, F. X., Smith, E. R. & Shilatifard, A. Born to run: control of transcription elongation
547 by RNA polymerase II. *Nat. Rev. Mol. Cell Biol.* **19**, 464–478 (2018).
- 548 31. Rahl, P. B. *et al.* C-Myc regulates transcriptional pause release. *Cell* **141**, 432–445
549 (2010).
- 550 32. Cisse, I. I. *et al.* Real-Time Dynamics of RNA Polymerase II Clustering in Live Human
551 Cells. *Science* **341**, 664–667 (2013).
- 552 33. Steurer, B. *et al.* Live-cell analysis of endogenous GFP-RPB1 uncovers rapid turnover of
553 initiating and promoter-paused RNA Polymerase II. *Proc. Natl. Acad. Sci.* **115**, E4368–
554 E4376 (2018).
- 555 34. Forero-Quintero, L. S. *et al.* Live-cell imaging reveals the spatiotemporal organization of
556 endogenous RNA polymerase II phosphorylation at a single gene. *bioRxiv*
557 2020.04.03.024414 (2020). doi:10.1101/2020.04.03.024414
- 558 35. Titov, D. V *et al.* XPB, a subunit of TFIIF, is a target of the natural product triptolide. *Nat.*
559 *Chem. Biol.* **7**, 182–188 (2011).
- 560 36. Gilchrist, D. A. *et al.* NELF-mediated stalling of Pol II can enhance gene expression by
561 blocking promoter-proximal nucleosome assembly. *Genes Dev.* **22**, 1921–1933 (2008).
- 562 37. Yung, T. M. C., Narita, T., Komori, T., Yamaguchi, Y. & Handa, H. Cellular dynamics of
563 the negative transcription elongation factor NELF. *Exp. Cell Res.* **315**, 1693–1705 (2009).
- 564 38. Fant CB, Levandowski CB, Gupta K, et al. TFIID Enables RNA Polymerase II Promoter-
565 Proximal Pausing. *Mol Cell.* **78** (4):785-793 (2020).
- 566 39. Shao, W. & Zeitlinger, J. Paused RNA polymerase II inhibits new transcriptional initiation.
567 *Nat. Genet.* **49**(7):1045-1051 (2017).
- 568 40. Jonkers, I., Kwak, H. & Lis, J. T. Genome-wide dynamics of Pol II elongation and its
569 interplay with promoter proximal pausing, chromatin, and exons. *Elife* **2014**, 1–25 (2014).

- 570 41. Henriques, T. *et al.* Stable Pausing by RNA Polymerase II Provides an Opportunity to
571 Target and Integrate Regulatory Signals. *Mol. Cell* **52**, 517–528 (2013).
- 572 42. Kellner, W. A., Bell, J. S. K. & Vertino, P. M. GC skew defines distinct RNA polymerase
573 pause sites in CpG island promoters. *Genome Res.* **25**, 1600–1609 (2015).
- 574 43. Szlachta, K. *et al.* Alternative DNA secondary structure formation affects RNA
575 polymerase II promoter-proximal pausing in human. *Genome Biol.* **19**, 89 (2018).
- 576 44. Chen, F., Gao, X., Shilatifard, A. & Shilatifard, A. Stably paused genes revealed through
577 inhibition of transcription initiation by the TFIIH inhibitor triptolide. *Genes Dev.* **29**, 39–47
578 (2015).
- 579 45. Nogales, E., Louder, R. K. & He, Y. Cryo-EM in the study of challenging systems: the
580 human transcription pre-initiation complex. *Curr. Opin. Struct. Biol.* **40**, 120–127 (2016).
- 581 46. Zhang, Z. *et al.* Rapid dynamics of general transcription factor TFIIB binding during
582 preinitiation complex assembly revealed by single-molecule analysis. *Genes Dev.* **30**,
583 2106–2118 (2016).
- 584 47. de Graaf, P. *et al.* Chromatin interaction of TATA-binding protein is dynamically regulated
585 in human cells. *J. Cell Sci.* **123**, 2663–2671 (2010).
- 586 48. Danko, C. G. *et al.* Signaling pathways differentially affect RNA polymerase II initiation,
587 pausing, and elongation rate in cells. *Mol. Cell* **50**, 212–222 (2013).
- 588 49. Krebs, A. R. *et al.* Genome-wide Single-Molecule Footprinting Reveals High RNA
589 Polymerase II Turnover at Paused Promoters. *Mol. Cell* **67**, 411–422 (2017).
- 590 50. Mulas, C. *et al.* Defined conditions for propagation and manipulation of mouse embryonic
591 stem cells. *Development* **146** (6) (2019).
- 592 51. Mylonas, C. & Tessarz, P. Transcriptional repression by FACT is linked to regulation of
593 chromatin accessibility at the promoter of ES cells. *Life Sci. Alliance* **1** (3) (2018).
- 594 52. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
595 **9**, 357–359 (2012).
- 596 53. Zhang, Y., Lin, Y. H., Johnson, T. D., Rozek, L. S. & Sartor, M. A. PePr: A peak-calling
597 prioritization pipeline to identify consistent or differential peaks from replicated ChIP-Seq
598 data. *Bioinformatics* **30**, 2568–2575 (2014).

- 599 54. Ramirez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data
600 analysis. *Nucleic Acids Res.* **44**, 160–165 (2016).
- 601 55. Hansen, P. *et al.* Q-nexus: a comprehensive and efficient analysis pipeline designed for
602 ChIP-nexus. *BMC Genomics* **17**, 873 (2016).
- 603 56. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
604 for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 605 57. Sorenson R, Johnson K, Adler F, S. L. RNAdecay: Maximum Likelihood Decay Modeling
606 of RNA Degradation Data. (2019).
- 607 58. Sergé, A., Bertaux, N., Rigneault, H. & Marguet, D. Dynamic multiple-target tracing to
608 probe spatiotemporal cartography of cell membranes. *Nat. Methods* **5**, 687–694 (2008).
- 609 59. Andrews, J. O. *et al.* qSR: a quantitative super-resolution analysis tool reveals the cell-
610 cycle dependent organization of RNA Polymerase I in live human cells. *Sci. Rep.* **8** (1),
611 7424 (2018).
- 612 60. Dobin, A. *et al.* STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21
613 (2013).
- 614 61. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for
615 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–
616 140 (2009).
- 617 62. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing
618 and microarray studies. *Nucleic Acids Res.* **43** (7) e47 (2015).
- 619 63. Mayer, A. & Churchman, L. S. Genome-wide profiling of RNA polymerase transcription at
620 nucleotide resolution in human cells with native elongating transcript sequencing. *Nat*
621 *Protoc.* **11**, 813–833 (2016).
- 622 64. Wamstad, J. A. *et al.* Dynamic and Coordinated Epigenetic Regulation of Developmental
623 Transitions in the Cardiac Lineage. *Cell* **151**, 206–220 (2012).
- 624 65. Illingworth, R. S. *et al.* The E3 ubiquitin ligase activity of RING1B is not essential for early
625 mouse development. *Genes Dev.* **29**, 1897–1902 (2015).
- 626 66. Mas, G. *et al.* Promoter bivalency favors an open chromatin architecture in embryonic
627 stem cells. *Nat. Genet.* **50**, 1452–1462 (2018).




Figure 1

1 **Figure 1 | H2A.Z.1 attenuates the release of RNAPII towards progressive elongation. a.**
2 Schematic diagram of dTAG system for rapid depletion of H2A.Z.1 protein levels. **b.**
3 Immunoblotting with anti-HA and anti-GAPDH antibodies in Control and dTAG-13 treated mESCs.
4 **c.** ChIP-seq heatmaps over 7,789 protein-coding genes for H2A.Z.1 in control and dTAG-13
5 treated cells. **d.** ChIP-seq heatmaps over 7,624 uniquely annotated genes for RNAPII for Control
6 (DMSO), DRB, and wash-off conditions. Genes are sorted by H3K4me3 levels. **e.** Same as (D)
7 but for H2A.Z.1. **f.** Scatterplot of H2A.Z.1 ChIP-seq logFC (dTAG-13 / Control) versus mRNA
8 (RNA-seq) logFC (dTAG-13 / Control). Spearman correlation is indicated in red ($\rho = -0.63$). **g.**
9 Heatmap of RNAPII (NET-seq) for Control and H2A.Z.1-depleted (dTAG-13) mESCs over 4,184
10 uniquely annotated protein-coding genes. Genes are sorted by gene length. **h.** Cumulative
11 distribution plot of RNAPII (NET-seq) Pausing Index for Control and H2A.Z.1-depleted (dTAG-13)
12 mESCs for 4,184 uniquely annotated protein-coding genes. Significance was calculated using a
13 paired Wilcoxon rank test. **i.** MA plot of Spt5 ChIP-seq between Control and dTAG-13 treated
14 mESCs. Significant differential Spt5 binding displays either logFC < -0.2 or logFC > 0.2 and a P
15 Value < 0.05. **j.** Single gene plots of ChIP-seq (H2A.Z.1 and Spt5), NET-seq (RNAPII), and RNA-
16 seq over the *Vapa* gene. Control and dTAG-13 datasets are displayed in the positive and negative
17 strands, respectively.

18

19

20

21

22

23








24

25

26

27

28



29 **Figure 2 | H2A.Z.1 controls NELF and RNAPII dynamics at a single molecule level. a.** Live-
30 cell direct image of pre-converted Dendra2-RNAPII (cyan) and super-resolution image of post-
31 converted Dendra2-RNAPII (red) and corresponding time-correlated photoactivation localization
32 microscopy (tcPALM) traces. Scale bar 5 μm and 5 nm (zoomed in clusters). **b.** Cumulative
33 distribution and histogram of RNAPII transient cluster lifetime between Control ($n = 360$ clusters)
34 and dTAG-13 ($n = 363$ clusters) measured by time correlated PALM (tcPALM). Significance is
35 calculated using an unpaired Wilcoxon rank test. **c.** Live-cell direct images of NELF-Halo in
36 Control and dTAG-13 conditions. Cells were treated with DMSO (no drug inhibition), DRB (50
37 μM), or Triptolide (50 μM) for 45 min. Scale bar 5 μm . **d.** Normalized intensity of NELF-Halo
38 clusters displayed in **(c)**. No drug inhibition ($n=42$), DRB ($n=35$), TRI ($n=56$). Significance was
39 calculated using an unpaired Wilcoxon rank test. **e.** FRAP analysis of NELF clusters. Images of
40 a Halo-NELF cell before (0 sec), and immediately after (1-10 sec) bleaching. The black box
41 indicates an unbleached control locus. The golden box indicates the position of the cluster on
42 which the FRAP beam was focused. **f.** The normalized recovery curve for NELF ($n = 23$ cells)
43 yielded a recovery fraction of $\sim 80\%$ during the 60 sec observation in Control (black) conditions
44 that increased to $\sim 90\%$ in dTAG-13 treated cells. Dots and shaded areas represent mean and
45 SEM values, respectively. The Welch unpaired t-test was used for significance. **g.** Mobile fraction
46 of in Control (black) and dTAG-13 (red) conditions. Error bars represent $\pm\text{SEM}$.

47

48

49

50

51


52

53

54

55

56



57 **Figure 3 | H2A.Z.1 controls RNAPII half-life of less stable promoters. a.** Schematic diagram
58 of the ChIP-nexus approach. Lambda (λ) exonuclease activity reveals transcription factor
59 footprints at near nucleotide resolution. Representative tracks of RNAPII ChIP-seq and RNAPII
60 ChIP-nexus over a single gene (*Rps9*). **b.** Histogram of the half-lives of paused RNAPII of 2,971
61 genes between Control (black) and dTAG-13 (red) conditions. Significance was calculated using
62 a paired Wilcoxon rank test. **c.** The half-life of paused RNAPII was calculated on the basis of an
63 exponential decay model. Normalized promoter proximal RNAPII density for the *Fgf4* gene is
64 shown over the course of TRI treatment (0, 10, 20, and 40 min) both for Control (black) and dTAG-
65 13 (red) conditions. **d.** Histograms of short (1.5-7.9 min), medium (8 -13.5 min), and long (13.6 -
66 23.5 min) RNAPII half-lives for Control and dTAG-13 conditions. Significance was calculated
67 using a paired Wilcoxon rank test. **e.** Boxplots measuring \log_2 FC (dTAG-13 / Control) of promoter
68 proximal RNAPII (ChIP-nexus) for the three different gene classes. Significance was calculated
69 using an unpaired Wilcoxon rank test. **f.** Same as (E) but for mRNA levels (RNA-seq). **g.** Same
70 as (E) but for gene body nascent RNA levels (NET-seq).

71

72

73

74

75

76

77

78

79

80

81

82

83




Figure 4

84 **Figure 4 | H2A.Z.1 controls Pre-initiation complex (PIC) recruitment at promoters.** **a.** Single
85 gene plot (*Ubb*) of RNAPII ChIP-nexus profiles over the course of Triptolide treatment (No TRI,
86 10 min, 20 min, and 40 min). RNAPII density is displayed both in the positive (blue) and negative
87 (red) strand. Initiating RNAPII is highlighted in yellow. **b.** Boxplots measuring \log_2 FC (dTAG-13
88 vs Control) of initiating RNAPII over the course of TRI treatment. Significance was calculated
89 using a Wilcoxon rank test. Schematic diagram displays ChIP-nexus RNAPII metaplots over the
90 Transcription Start Site (TSS) whereas the dotted box denotes the area we used to quantify
91 initiating RNAPII density ($n = 3,298$ genes). **c.** Single gene plot (*Eif4a2*) of TBP, TFIID, RNAPII
92 ChIP-nexus profiles in Control conditions. ChIP-nexus density is displayed both in the positive
93 (blue) and negative (red) strand. Initiating RNAPII, and PIC are highlighted in yellow. **d.** Metaplots
94 of TFIIB ChIP-nexus in Control conditions with (“TRI 40min”) or without (“No TRI”) triptolide. **e.**
95 Metaplots of TFIIB ChIP-nexus in H2A.Z.1-depleted (dTAG-13) conditions with (“TRI 40min”) or
96 without (“No TRI”) triptolide. **f.** Boxplots measuring \log_2 FC (TRI 40min vs No TRI) TFIIB density
97 between Control and dTAG-13 in an area 250 bp upstream of the TSS ($n = 3,095$ genes).
98 Significance was calculated using a Wilcoxon rank test. **g.** Schematic diagram of how H2A.Z.1
99 controls proper execution of transcription programs. H2A.Z.1 blocks recruitment of the PIC and
100 also widens the barrier for elongating RNAPII by promoting a more paused state (left panel). In
101 the absence of H2A.Z.1, PIC is recruited faster while RNAPII is released in a faster rate from the
102 promoter which is accompanied by faster NELF dynamics (right panel).

103

104

105

106

107

108

109

110

111

112